+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Post-Operative Pain - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 302 Pages
  • July 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5137254
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Post-Operative Pain - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H2 2020, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 5, 21, 18, 4, 33, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 3 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Post-Operative Pain - Overview

Post-Operative Pain - Therapeutics Development

Post-Operative Pain - Therapeutics Assessment

Post-Operative Pain - Companies Involved in Therapeutics Development

Post-Operative Pain - Drug Profiles

Post-Operative Pain - Dormant Projects

Post-Operative Pain - Discontinued Products

Post-Operative Pain - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Post-Operative Pain, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H2 2020
  • Post-Operative Pain - Pipeline by Adare Pharmaceuticals Inc, H2 2020
  • Post-Operative Pain - Pipeline by Adynxx Inc, H2 2020
  • Post-Operative Pain - Pipeline by Algomedix Inc, H2 2020
  • Post-Operative Pain - Pipeline by Altus Formulation Inc, H2 2020
  • Post-Operative Pain - Pipeline by AmacaThera Inc, H2 2020
  • Post-Operative Pain - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2020
  • Post-Operative Pain - Pipeline by AngioChem Inc, H2 2020
  • Post-Operative Pain - Pipeline by Antibe Therapeutics Inc, H2 2020
  • Post-Operative Pain - Pipeline by Bayer AG, H2 2020
  • Post-Operative Pain - Pipeline by Benuvia Therapeutics Inc, H2 2020
  • Post-Operative Pain - Pipeline by Cadila Healthcare Ltd, H2 2020
  • Post-Operative Pain - Pipeline by Cali Pharmaceuticals LLC, H2 2020
  • Post-Operative Pain - Pipeline by Camurus AB, H2 2020
  • Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H2 2020
  • Post-Operative Pain - Pipeline by Cellix Bio Pvt Ltd, H2 2020
  • Post-Operative Pain - Pipeline by CerSci Therapeutics Inc, H2 2020
  • Post-Operative Pain - Pipeline by Chromocell Corp, H2 2020
  • Post-Operative Pain - Pipeline by Concentric Analgesics Inc, H2 2020
  • Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H2 2020
  • Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H2 2020
  • Post-Operative Pain - Pipeline by Douleur Therapeutics Inc, H2 2020
  • Post-Operative Pain - Dormant Projects, H2 2020
  • Post-Operative Pain - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Post-Operative Pain, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AcelRx Pharmaceuticals Inc
  • Adare Pharmaceuticals Inc
  • Adynxx Inc
  • Algomedix Inc
  • Altus Formulation Inc
  • AmacaThera Inc
  • Andros Pharmaceuticals Co Ltd
  • AngioChem Inc
  • Antibe Therapeutics Inc
  • Bayer AG
  • Benuvia Therapeutics Inc
  • Cadila Healthcare Ltd
  • Cali Pharmaceuticals LLC
  • Camurus AB
  • Cara Therapeutics Inc
  • Cellix Bio Pvt Ltd
  • CerSci Therapeutics Inc
  • Chromocell Corp
  • Concentric Analgesics Inc
  • Cytogel Pharma LLC
  • Dompe Farmaceutici SpA
  • Douleur Therapeutics Inc
  • DURECT Corp
  • Esteve Pharmaceuticals SA
  • Euclises Pharmaceuticals Inc
  • Eupraxia Pharmaceuticals Inc
  • Flexion Therapeutics Inc
  • Fujimoto Pharmaceutical Corp
  • Grunenthal GmbH
  • H. Lundbeck AS
  • Hana Pharm Co Ltd
  • Heron Therapeutics Inc
  • Innocoll AG
  • InSitu Biologics LLC
  • Insys Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • iX Biopharma Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Hengrui Pharmaceutical Co Ltd
  • Liquidia Technologies Inc
  • Lumosa Therapeutics Co Ltd
  • Luye Pharma Group Ltd
  • Medical Developments International Ltd
  • MedinCell SA
  • Mundipharma International Ltd
  • Neokera LLC
  • Neumentum Inc
  • NeurAxon Pharma Inc
  • NeuroPn Therapeutics LLC
  • Ocular Therapeutix Inc
  • Pacira BioSciences Inc
  • PainReform Ltd
  • Pharmaleads SA
  • Pharmazz Inc
  • PhytoHealth Corp
  • PolyPid Ltd
  • Quoin Pharmaceuticals Ltd
  • Revogenex Inc
  • RHNanopharmacuticals LLC
  • Rottapharm Biotech Srl
  • Sedor Pharmaceuticals LLC
  • Seelos Therapeutics, Inc.
  • Serina Therapeutics Inc
  • Shijiazhuang Yiling Pharmaceutical Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SiteOne Therapeutics Inc
  • Sotex Pharm Firm
  • SteadyMed Therapeutics Inc
  • Taiwan Liposome Co Ltd
  • Teikoku Pharma USA Inc
  • Theracaine LLC
  • Trevena Inc
  • Vertex Pharmaceuticals Inc
  • Virpax Pharmaceuticals Inc
  • Vivozon Inc
  • Xgene Pharmaceutical Inc
  • Xigen SA
  • Yichang Humanwell Pharmaceutical Co Ltd